THE JOHNS HOPKINS UNIVERSITY - A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS

On Dec 8, 2025, Department of Health and Human Services obligated $4,617,504 to THE JOHNS HOPKINS UNIVERSITY for a phase ii, randomized, double-blind, placebo controlled trial to evaluate the antiviral activity, safety, and pharmacokinetics of novartis eyu688 against dengue virus 2 infection in a controlled huma…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost no fee contract. Competition extent: full and open competition. Performance is located in BALTIMORE, MD. The contract is scheduled through Jul 22, 2026 — approximately 1 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.